Adjuvant Therapies of Cancer
Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therap...
| Other Authors: | , , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1982, 1982
|
| Edition: | 1st ed. 1982 |
| Series: | Recent Results in Cancer Research
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 37. Specific Active Immunotherapy in Lung Cancer: The Induction of Long-Lasting Cellular Responses to Tumour-Associated Antigens
- 38. Malnutrition in Lung Cancer: Incidence, Prognostic Implications, and Pathogenesis
- 39. Follow-Up of a Randomized Trial for Oat Cell Carcinoma Evaluating the Efficacy of Peripheral Intravenous Nutrition (PIVN) as Adjunct Treatment
- VI. Melanoma
- 40. Clinical Trials of Chemotherapy and Chemoimmunotherapy in Primary Malignant Melanoma
- 41. Trial 6: Randomized Study of Prolonged Chemotherapy, Immunotherapy, and Chemoimmunotherapy as an Adjuvant to Surgery for Stage I and II Melanoma. A Progress Report
- 42. Current Status of Melanoma Chemotherapy and Immunotherapy
- VII. Testicular Neoplasia
- 43. Adjuvant Therapy of Testicular Carcinoma
- VIII. Gastrointestinal Neoplasms
- 44. Adjuvant 5-Fluorouracil and BCNU Chemotherapy in Gastric Cancer: 3-Year Results
- 45. Adjuvant Chemotherapy in Colon and Gastric Cancer
- 29. Adjuvant Chemoimmunotherapy with LMF Plus BCG in Node-Negative and Node-Positive Breast Cancer — Intermediate Report at 4 Years
- 30. Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up
- 31. Short-Term and Long-Term Effects of Chemoimmunotherapy on Granulopoiesis: Adjuvant Therapy of Breast Cancer
- 32. A New Adjuvant Treatment with Polyadenylic- Polyuridylic Acid in Operable Breast Cancer
- V. Lung Carcinoma
- 33. Metastatic CNS Disease in Small Cell Carcinoma of the Bronchus: The Role of Radiotherapy and Chemotherapy
- 34. Interim Results of EORTC Protocol 08742: Comparison, After Irradiation of Locally Advanced Squamous Cell Bronchial Carcinoma, of Abstention, Immunotherapy, CombinationChemotherapy or Chemoimmunotherapy
- 35. Immunologically Defined Prognostic Subgroups as Predictors of Response to BCG Immunotherapy
- 36. Intrapleural BCG Immunotherapy of Lung Cancer Patients
- I. General Considerations
- 1. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications
- 2. Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights
- 3. Markers of Minimal Residual Disease
- 4. Radiotherapy as Adjuvant Local Therapy of Local Tumors
- II. Hemopoietic and Lymphoid Neoplasias
- 5. Comparison of HLA Phenotypes in Long-Term Survivors with Acute Lymphoblastic Leukemia Treated with Immunotherapy Versus Chemotherapy
- 6. An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor- Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up
- 7. Poor-Prognosis Acute Lymphoblastic Leukemias
- 8. Therapeutic Effectiveness of Neuraminidase- Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia
- 9. Maintenance Chemoimmunotherapy of Nonlymphoblastic Acute Leukemias
- 10. Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity
- 11. The Finnish Leukaemia Group: Levamisole in Maintenance Therapy of Acute Myeloid Leukemia in Adults
- 12. Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation
- 13. Prevention of Blastic Crisis in Ph1 -Positive Chronic Myeloid Leukemia
- 14. A Southwest Oncology Group: Chemotherapy Versus Chemotherapy Plus Radiotherapy in Treatment of Stage III Hodgkin’s Disease
- 15. Maintenance Immunotherapy with BCG in Non-Hodgkin’s Malignant Lymphomas: A Progress Report of a Randomized Trial
- III. Bone Tumors
- 16. Role of Lung Irradiation in the Adjuvant Treatment of Osteosarcoma
- 17. Adjuvant Interferon Treatment of Human Osteosarcoma
- 18. A Strategic Adjuvant Therapy ofOsteosarcoma
- 19. Ewing’s Sarcoma: Treatment with High-Dose Radiation and Adjuvant Chemotherapy
- 20. Adjuvant Chemotherapy in Ewing’s Sarcoma Patients
- 21. Early Results of Combined Modality Therapy of Patients with Ewing’s Sarcoma
- 22. Ewing’s Sarcoma: 5-Year Survival Under Adjuvant Chemotherapy
- IV. Breast Carcinoma
- 23. Natural History of Breast Cancer
- 24. Adjuvant Chemotherapy in Breast Cancer
- 25. Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience
- 26. Follow-Up Results from a Randomized Trial for T3 and T4 Breast Cancer Patients: Previous BCG Immunotherapy Improves Response to Chemotherapy in the Relapse Patient
- 27. Adjuvant Treatment of Node-Positive Breast Cancer with Adriamycin-Cyclophosphamide with or Without Radiation Therapy: Interim Results of an Ongoing Clinical Trial
- 28. A Randomized Trial of Postoperative Five- Versus Three-Drug Chemotherapy After Mastectomy: A Cancer and Leukemia Group B (CALGB) Study
- 46. Chemotherapy of Metastatic Gastrointestinal Cancers: Prospects for Future Adjuvant Systemic Therapies
- 47. Chemotherapy of Carcinomas of the Digestive Tract
- IX. Conclusions and Prospects
- 48. Clinical Trials on Adjuvant Therapies in Cancer: Short-Term and Long-Term Results
- 49. Long-Term Costs of Adjuvant Radiotherapy
- 50. Long-Term Cost of Combined Radiotherapy and Chemotherapy
- 51. Studies of Clonogenic Human Tumor Stem Cells
- 52. Current Status of Clinical Trials of m-AMSA, Dihydroxyanthracenedione, and Deoxycoformycin
- 53. Three New Agents for Immunotherapy Trials: Azimexon, Bestatin, and Tuftsin
- 54. Emerging Immunologic Approaches to Treatment of Neoplastic Diseases
- 55. Cellular Interactions Modulating Host Resistance to Tumours
- 56. Preliminary Clinical Results with Norgamen (Thioproline) and Revercan (S-Amino-2- Thiazoline): The First Inducers of Reverse Transformation
- 57. Biologic Response Modifiers and Adjuvant Chemotherapy: Consideration of Selected Preclinical Investigations in Relation to Clinical Potential